06:34 AM EDT, 08/21/2025 (MT Newswires) -- CVS Health ( CVS ) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo, in its commercial or Affordable Care Act plans for now, Reuters reported Thursday, citing company spokesperson David Whitrap.

The company cited clinical, financial and regulatory reasons, including current federal guidelines that recommend only three older HIV prevention drugs, the report said.

Yeztugo, a twice-yearly injection priced at over $28,000 per year, is still under negotiation between Gilead and CVS, Reuters said, citing a source familiar with the situation.

Gilead said it is on track to secure 75% US insurance coverage by the end of 2025 and 90% by mid-2026, according to the report.

Reuters also said that other major pharmacy benefit managers, such as UnitedHealth Group's ( UNH ) OptumRx, are reviewing the drug for potential coverage, while Cigna's ( CI ) Express Scripts did not respond to requests for comment.

It added that US government programs, including Medicare and the Veterans Administration, already cover Yeztugo.

CVS Health ( CVS ) and Gilead Sciences did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)